Danese S - Search Results

1

Biological therapy for ulcerative colitis: what is after anti-TNF.

Fiorino G, Cesarini M, Danese S. Fiorino G, et al. Among authors: danese s. Curr Drug Targets. 2011 Sep;12(10):1433-9. doi: 10.2174/138945011796818225. Curr Drug Targets. 2011. PMID: 21466492 Review.

2

Biological therapies for inflammatory bowel disease: research drives clinics.

Danese S, Semeraro S, Armuzzi A, Papa A, Gasbarrini A. Danese S, et al. Mini Rev Med Chem. 2006 Jul;6(7):771-84. doi: 10.2174/138955706777698624. Mini Rev Med Chem. 2006. PMID: 16842127 Review.

3

Biological agents for ulcerative colitis: hypes and hopes.

Danese S, Angelucci E, Malesci A, Caprilli R. Danese S, et al. Med Res Rev. 2008 Mar;28(2):201-18. doi: 10.1002/med.20103. Med Res Rev. 2008. PMID: 17464967 Review.

4

Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance.

Danese S, Pagano N, Angelucci E, Stefanelli T, Repici A, Omodei P, Daperno M, Malesci A. Danese S, et al. Curr Med Chem. 2007;14(14):1489-97. doi: 10.2174/092986707780831104. Curr Med Chem. 2007. PMID: 17584058 Review.

5

Cytapheresis in inflammatory bowel diseases: current evidence and perspectives.

Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A. Danese S, et al. Digestion. 2008;77(2):96-107. doi: 10.1159/000122473. Epub 2008 Apr 1. Digestion. 2008. PMID: 18382085 Review.

6

Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades.

Deban L, Correale C, Vetrano S, Malesci A, Danese S. Deban L, et al. Among authors: danese s. Am J Pathol. 2008 Jun;172(6):1457-66. doi: 10.2353/ajpath.2008.070593. Epub 2008 May 5. Am J Pathol. 2008. PMID: 18458096 Free PMC article. Review.

7

Tolerance in intestinal inflammation and cancer.

Vulcano M, Danese S, Sica A. Vulcano M, et al. Among authors: danese s. Curr Drug Targets. 2008 May;9(5):404-12. doi: 10.2174/138945008784221143. Curr Drug Targets. 2008. PMID: 18473769 Review.

8

New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets.

Stefanelli T, Malesci A, Repici A, Vetrano S, Danese S. Stefanelli T, et al. Among authors: danese s. Curr Drug Targets. 2008 May;9(5):413-8. doi: 10.2174/138945008784221170. Curr Drug Targets. 2008. PMID: 18473770 Review.

9

Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis.

Vetrano S, Correale C, Borroni EM, Pagano N, Savino B, Locati M, Malesci A, Repici A, Danese S. Vetrano S, et al. Among authors: danese s. Int J Immunopathol Pharmacol. 2008 Apr-Jun;21(2):401-7. doi: 10.1177/039463200802100219. Int J Immunopathol Pharmacol. 2008. PMID: 18547485 Free article.

10

Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.

Danese S. Danese S. Dig Liver Dis. 2008 Jul;40 Suppl 2:S225-8. doi: 10.1016/S1590-8658(08)60530-7. Dig Liver Dis. 2008. PMID: 18598993

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,214 results

Search Page

Filters